secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2025-02-26T23:59:59+00:00
Accession:  0001493152-25-008268
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kairos Pharma presents preclinical data for KROS 101 and KROS 401 at AACR IO
----------------------------------------------------------------------------

- KROS 101 (GITR agonist) inhibited tumor growth in melanoma model and increased CD4+/CD8+ T cell proliferation.
- KROS 101 prevented T cell exhaustion, a key advantage over prior GITR antibody TRX518.
- KROS 401 peptide inhibitor reduced M2 macrophages and showed anti-tumor effect in glioma-bearing mice.
- Data presented at AACR Immuno-Oncology conference in Los Angeles, February 23-26, 2025.
- CEO highlighted potential of KROS platform to address T cell exhaustion and reprogram tumor microenvironment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000149315225008268/0001493152-25-008268-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000149315225008268/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-008268

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer